5 More Sizzling Stocks to Buy Under $10 With Massive Implied Upside


This is another microcap biotech play that could be a big winner. Durect Corp. (NASDAQ: DRRX) is a biopharmaceutical company that researches and develops medicines based on its epigenetic regulator and pharmaceutical programs.

The company offers Alzetproduct line, which consists of osmotic pumps and accessories used for research in mice, rats and other laboratory animals. It also develops DUR-928, an endogenous, orally bioavailable small molecule that is in Phase 2b clinical trial to play a regulatory role in lipid homeostasis, inflammation and cell survival, as well as completed Phase 1b clinical trial to treat patients with nonalcoholic steatohepatitis.

In addition, Durect offers Posimir, a post-surgical pain product to deliver bupivacaine in adults. It markets and sells its Alzet lines through its direct sales force in the United States, as well as through a network of distributors in Japan, Europe and elsewhere. The company has strategic collaboration and other agreements with Virginia Commonwealth University Intellectual Property Foundation, Indivior UK, Santen Pharmaceutical, Sandoz and Gilead Sciences.

A huge $8 price target accompanies Oppenheimer’s Outperform rating is well above the lower $6.67 consensus target. The stock has traded below $2 since the beginning of April.


This is an interesting idea for those looking for a small-cap gaming idea. PlayAGS Inc. (NYSE: AGS) designs and supplies gaming products. The company operates through three segments.

The Electronic Gaming Machines segment includes server-based and back-office systems. The Table Products includes live felt table games, side bets and card shuffler. The Interactive Social Casino Games segment provides casino games on desktop and mobile devices. Its products include slots, cabinets, interactive and table games.

The analysts at Truist Securities recently started coverage with a Buy rating and a $12 price target. Though the stock broke above $9.50 late in the week, the consensus target is just $6.03.

These are five stocks for aggressive investors looking to get share count leverage on companies that have sizable upside potential. While not suited for all investors, these are not penny stocks with absolutely no track record or liquidity, and major Wall Street firms have research coverage.

Sponsored: Tips for Investing

A financial advisor can help you understand the advantages and disadvantages of investment properties. Finding a qualified financial advisor doesn’t have to be hard. SmartAsset’s free tool matches you with up to three financial advisors who serve your area, and you can interview your advisor matches at no cost to decide which one is right for you. If you’re ready to find an advisor who can help you achieve your financial goals, get started now.

Investing in real estate can diversify your portfolio. But expanding your horizons may add additional costs. If you’re an investor looking to minimize expenses, consider checking out online brokerages. They often offer low investment fees, helping you maximize your profit.